Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study of a primary chemotherapy regimen in breast cancer patients at
risk of developing cardiotoxicity. The aim of the study is to evaluate the response rate at
surgery.